| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1017036865 |
| P356 | DOI | 10.1186/S12885-016-2587-4 |
| P932 | PMC publication ID | 4960681 |
| P698 | PubMed publication ID | 27456970 |
| P50 | author | Diethelm Wallwiener | Q1223199 |
| Sabine Kasimir-Bauer | Q38290923 | ||
| Tanja Fehm | Q38294268 | ||
| Bahriye Aktas | Q83188500 | ||
| P2093 | author name string | Klaus Pantel | |
| Volkmar Müller | |||
| Wolfgang Janni | |||
| Mitra Tewes | |||
| DETECT Study Group | |||
| P2860 | cites work | Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients | Q21284707 |
| HER-2 gene amplification can be acquired as breast cancer progresses | Q24563115 | ||
| Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. | Q33777431 | ||
| HER2-positive circulating tumor cells in breast cancer | Q33802925 | ||
| Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? | Q33820233 | ||
| Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. | Q33847889 | ||
| Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). | Q34613506 | ||
| Receptor conversion in distant breast cancer metastases | Q34989060 | ||
| Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss | Q35082619 | ||
| Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis | Q35546265 | ||
| Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor | Q35776216 | ||
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors | Q35808400 | ||
| Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine | Q35909577 | ||
| Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status | Q36458793 | ||
| Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. | Q36924473 | ||
| Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. | Q37090760 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? | Q37316222 | ||
| Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients | Q37360176 | ||
| Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells | Q37360230 | ||
| HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis | Q37893534 | ||
| Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer | Q38070396 | ||
| HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact | Q38114240 | ||
| ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer | Q38409832 | ||
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial | Q39712731 | ||
| Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system | Q45733272 | ||
| Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. | Q46167485 | ||
| Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis | Q46670276 | ||
| Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients | Q47586016 | ||
| Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer | Q48334436 | ||
| Breast cancer subtypes and outcome after local and regional relapse. | Q51037092 | ||
| Should liver metastases of breast cancer be biopsied to improve treatment choice? | Q51054351 | ||
| Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. | Q51507853 | ||
| Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. | Q53433727 | ||
| Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. | Q54542518 | ||
| Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. | Q54568017 | ||
| HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. | Q54614183 | ||
| Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. | Q54619824 | ||
| Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. | Q54732957 | ||
| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. | Q55043149 | ||
| Biopsy of liver metastasis for women with breast cancer: Impact on survival | Q57580716 | ||
| Change of HER-2/neu status in a subset of distant metastases from breast carcinomas | Q80350820 | ||
| The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients | Q80531692 | ||
| HER2 status in a population-derived breast cancer cohort: discordances during tumor progression | Q84566644 | ||
| Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells | Q85060184 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 522 | |
| P577 | publication date | 2016-07-25 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients | |
| P478 | volume | 16 |
| Q99604931 | A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells |
| Q51081148 | About HER2 monitoring using liquid biopsies in patients with gastric cancer. |
| Q39054166 | Breast Cancer Metastasis Associations with Clinicopathological Characteristics in Mexican Women Younger than 40 Years of Age |
| Q55692870 | Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. |
| Q64245475 | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
| Q92373173 | Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC |
| Q89977540 | Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value |
| Q50642054 | Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. |
| Q28067549 | Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack |
| Q47397566 | Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients |
| Q91974779 | Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance |
| Q42267344 | Evaluation of Circulating Endometrial Cells as a Biomarker for Endometriosis |
| Q57283292 | HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer |
| Q64879795 | Lymph-circulating tumor cells show distinct properties to blood-circulating tumor cells and are efficient metastatic precursors. |
| Q89579652 | Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer |
| Q64106622 | Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells |
| Q38621053 | Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. |
| Q41233528 | Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy |
| Q42669105 | Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer. |
| Q93120565 | PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study |
| Q92081475 | The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy |
| Q41612814 | Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry |
Search more.